Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on treatments for inflammatory diseases and severe respiratory disorders, announced that CEO Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET.

A live webcast and replay will be available on the company’s investor relations website.

News Market Reaction – UPB

+5.24%

17 alerts

+5.24% Session close to close

+4.4% Peak in 4 hr 50 min

$427.74M Market Cap

0.6x Rel. Volume

In the Jun 3 session, UPB gained 5.24%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.4% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.2% in the session following this news. A strong positive reaction aligns with the company’s pattern of constructive responses to clinical and strategic updates, such as prior earnings and Phase 3 planning news that saw generally supportive moves. However, past trading around conference presentations and data events has not always been uniformly positive, indicating sentiment can shift quickly. Investors have monitored cash runway figures in the $294.6–341.5 million range and ongoing trial progress when reassessing valuation.

Key Figures

Cash balance: $294.6 million Net loss: $40.6 million Net loss per share: $0.75 +5 more

8 metrics

Cash balance $294.6 million Cash, cash equivalents and short-term investments as of March 31, 2026

Net loss $40.6 million Net loss for the quarter ended March 31, 2026

Net loss per share $0.75 Net loss per share for the quarter ended March 31, 2026

Collaboration revenue $1.0 million Collaboration revenue from Maruho for the three months ended March 31, 2026

ATM program size $150,000,000 Maximum aggregate amount of common stock in at-the-market offering with Leerink Partners

ATM commission 3.0% Maximum commission rate on gross proceeds under sales agreement with Leerink Partners

Shares outstanding 54,419,986 Common shares outstanding as of March 20, 2026 per Schedule 13G/A

Year-end cash $341.5 million Cash, cash equivalents and short-term investments as of December 31, 2025

Historical Context

5 past events · Latest: May 18 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 18	Phase 2 data update	Positive	-6.4%	Reported improved asthma control and reduced steroid use in VIBRANT trial participants.
May 13	Quarterly earnings	Neutral	+4.6%	Detailed Q1 2026 results, higher expenses, and cash runway through 2027.
Apr 17	Conference presentation plans	Neutral	-1.1%	Announced upcoming VIBRANT Phase 2 data presentations at ATS 2026.
Mar 26	Phase 3 strategy, earnings	Positive	+3.4%	Outlined Phase 3 plan for verekitug and reported Q4 and 2025 results.
Feb 26	Additional trial analyses	Neutral	+2.1%	Planned additional VIBRANT analyses presentation at AAAAI 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Most prior news events showed price moves generally aligned with the news tone, with one notable divergence where positive Phase 2 data coincided with a negative price reaction.

Recent Company History

Over the past six months, UPB has focused on advancing its lead antibody verekitug through mid‑stage studies in severe asthma and CRSwNP, while preparing Phase 3 programs targeted for Q1 2027. Clinical updates, including VIBRANT and VALIANT data, have generally been positive, and earnings reports emphasized substantial cash balances expected to fund operations through 2027. Price reactions have mostly aligned with news tone, though one Phase 2 data release on May 18, 2026 saw a negative move despite favorable efficacy results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Goldman Sachs 47^th Annual Global Healthcare Conference on Wednesday, June 10, 2026, at 10:40 a.m. ET.

A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay will be available on the Company's website following the presentation.

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com

FAQ

When will Upstream Bio (UPB) present at the Goldman Sachs 47th Annual Global Healthcare Conference?

Upstream Bio will present on June 10, 2026, at 10:40 a.m. ET. According to Upstream Bio, CEO Rand Sutherland, MD, will join a fireside chat as part of the Goldman Sachs 47th Annual Global Healthcare Conference agenda.

How can investors watch Upstream Bio's UPB presentation at the Goldman Sachs 2026 healthcare conference?

Investors can watch via a live webcast on Upstream Bio’s investor website. According to Upstream Bio, the stream will be available under the Events tab on the Investors section on the day of the Goldman Sachs conference presentation.

Will a replay of Upstream Bio's (NASDAQ: UPB) Goldman Sachs healthcare conference presentation be available?

Yes, a replay will be available on Upstream Bio’s website after the event. According to Upstream Bio, investors can access the replay in the Investors section, providing on-demand viewing of the June 10, 2026, fireside chat.

Who is representing Upstream Bio (UPB) at the Goldman Sachs 47th Annual Global Healthcare Conference?

CEO Rand Sutherland, MD, will represent Upstream Bio at the conference. According to Upstream Bio, he will participate in a scheduled fireside chat session on June 10, 2026, at 10:40 a.m. ET, highlighting the company’s clinical-stage focus.

What type of company is Upstream Bio (UPB) presenting at the Goldman Sachs 2026 healthcare conference?

Upstream Bio is a clinical-stage company developing treatments for inflammatory diseases. According to Upstream Bio, its initial focus is on severe respiratory disorders, and the firm will discuss its work during a fireside chat at the Goldman Sachs healthcare conference.